Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g Vct5 Regulatory News (MIG5)

Share Price Information for Maven I&g Vct5 (MIG5)

Share Price is delayed by 15 minutes
Get Live Data
28.80    0.00 (0.00%)
Bid:
27.80
Ask:
29.80
Spread: 2.00 (7.194%)
Market Cap: £76.28m
MIG5 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g Vct5 Share Chart

Issue of Equity

5 Apr 2024 15:49

RNS Number : 5598J
Maven Income and Growth VCT 5 PLC
05 April 2024
 

Maven Income and Growth VCT 5 PLC (the Company)

 

Issue of Equity

 

On 13 October 2023, the Company launched an offer for subscription for new ordinary shares of 10p each (Ordinary Shares) to raise up to £5 million, with an over-allotment facility for up to a further £2.5 million (the Offer).

 

Pursuant to the Offer, a total of £2,338,474 of valid applications were received in the period from 9.00am on 21 March 2024 up to and including 9.00am on 5 April 2024 in respect of the 2023/2024 tax year. This is the final allotment in respect of the 2023/2024 tax year and, as a result, the Company has issued and allotted 7,209,045 new Ordinary Shares on 5 April 2024. In accordance with the allotment formula set out in the prospectus for the Offer, the offer prices at which the shares were issued were in the range of 31.52p to 32.36p per Ordinary Share and, as a result, the number of Ordinary Shares now in issue is 211,914,797. Therefore, the total number of voting rights in the Company is 211,914,797. The total amount raised by the Company for the 2023/2024 tax year to 5 April 2024 is £6,262,885.

 

In respect of this allotment, an application will be made by the Company to the FCA and to the London Stock Exchange for the new Ordinary Shares so issued to be admitted to the Official List and to trading on the London Stock Exchange's main market for listed securities. It is expected that the admission of the new Ordinary Shares will become effective, and dealings will commence, on or around 8 April 2024.

 

The above statement of Voting Capital may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The Board of the Company intends that an allotment in respect of applications for the 2024/2025 tax year will take place on, or around, 1 May 2024. For this allotment, and those made to date, the Company's Offer has received applications totalling £6,554,185.

 

For further information, please contact:

 

Maven Capital Partners UK LLP

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

 

Maven Capital Partners UK LLP

Secretary

 

5 April 2024

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEQKPBQQBKDOQK
Date   Source Headline
27th Mar 202510:25 amRNSUpdate re: Offers for Subscription
21st Mar 20254:35 pmRNSNet Asset Value(s)
12th Mar 20254:54 pmRNSAnnual Financial Report
26th Feb 20254:41 pmRNSTransaction in Own Shares
26th Feb 202510:33 amRNSUnaudited NAV and Proposed Final Dividend
19th Feb 202510:12 amRNSIssue of Equity
28th Jan 202512:15 pmRNSStatement re Offer for Subscription
18th Dec 20249:35 amRNSIssue of Equity
17th Dec 20243:27 pmRNSDirectorate Change
13th Dec 20242:45 pmRNSUnaudited Net Asset Value
14th Nov 20242:58 pmRNSResult of General Meeting
8th Oct 20245:01 pmRNSTransaction in Own Shares
4th Oct 20244:18 pmRNSTransaction in Own Shares
27th Sep 20244:31 pmRNSPublication of a Prospectus
6th Sep 20249:47 amRNSIssue of Equity
5th Sep 20242:28 pmRNSStatement re Dividend Investment Scheme
5th Sep 20241:36 pmRNSUnaudited Net Asset Value
12th Jul 20244:37 pmRNSTransaction in Own Shares
12th Jul 20244:09 pmRNSHalf-year Report
10th Jul 20245:05 pmRNSTransaction in Own Shares
5th Jul 202412:38 pmRNSStatement re NAV and Interim Dividend
18th Jun 202411:53 amRNSStatement re Intended Offers for Subscription
9th May 20244:05 pmRNSTransaction in Own Shares
3rd May 20249:28 amRNSIssue of Equity
1st May 202410:10 amRNSIssue of Equity
26th Apr 20242:44 pmRNSUnaudited NAV - Dividend Investment Scheme
23rd Apr 20242:27 pmRNSResult of AGM
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:49 pmRNSIssue of Equity
27th Mar 202410:31 amRNSIssue of Equity
22nd Mar 20244:25 pmRNSStatement re Offer for Subscription
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
20th Mar 20243:48 pmRNSUnaudited Net Asset Value
8th Mar 20242:57 pmRNSAnnual Financial Report
15th Feb 20244:45 pmRNSTransaction in Own Shares
8th Feb 202410:33 amRNSDirector/PDMR Shareholding
8th Feb 202410:12 amRNSIssue of Equity
7th Feb 20243:09 pmRNSDividend Declaration
19th Dec 20233:28 pmRNSIssue of Equity
18th Dec 20235:24 pmRNSUnaudited Net Asset Value
9th Nov 20233:51 pmRNSResult of General Meeting
20th Oct 20234:13 pmRNSTransaction in Own Shares
13th Oct 20234:56 pmRNSPublication of a Prospectus
4th Oct 20234:03 pmRNSNet Asset Value(s)
29th Aug 20239:15 amRNSDirectorate Change
24th Jul 202311:16 amRNSHalf-year Report
21st Jul 20234:43 pmRNSTransaction in Own Shares
21st Jul 20239:48 amRNSIssue of Equity
17th Jul 202310:57 amRNSNet Asset Value - Dividend Investment Scheme
11th Jul 20234:47 pmRNSNet Asset Value

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.